Insilico Medicine brings AI-powered " ChatPandaGPT " to its target discovery platform
Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-powered drug discovery company, has integrated advanced AI chat functionality based on recent advances in large language models into its PandaOmics platform. The new feature, "ChatPandaGPT," enables researchers to have natural language conversations with the platform and efficiently navigate and analyze large datasets, facilitating the discovery of potential therapeutic targets and biomarkers in a more efficient manner. (Source: World Pharma News)
Source: World Pharma News - March 22, 2023 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news
'Biohybrid' device could restore function in paralysed limbs
Researchers have developed a new type of neural implant that could restore limb function to amputees and others who have lost the use of their arms or legs.
In a study carried out in rats, researchers from the University of Cambridge used the device to improve the connection between the brain and paralysed limbs. The device combines flexible electronics and human stem cells - the body's 'reprogrammable' master cells - to better integrate with the nerve and drive limb function. (Source: World Pharma News)
Source: World Pharma News - March 22, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned, independently operated subsidiary of Bayer AG, announced a collaboration with Rune Labs and Emerald Innovations focused on using wearable and invisible contactless digital health technology to improve monitoring and data collection for Parkinson's disease clinical trials. (Source: World Pharma News)
Source: World Pharma News - March 21, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
Scientists use tardigrade proteins for human health breakthrough
University of Wyoming researchers' study of how microscopic creatures called tardigrades survive extreme conditions has led to a major breakthrough that could eventually make life-saving treatments available to people where refrigeration isn’t possible.
Thomas Boothby, an assistant professor of molecular biology, and colleagues have shown that natural and engineered versions of tardigrade proteins can be used to (Source: World Pharma News)
Source: World Pharma News - March 20, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
Novartis today announced the U.S. Food and Drug Administration (FDA) granted approval for Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. The FDA also approved liquid formulations of Tafinlar and Mekinist, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as one year of age. (Source: World Pharma News)
Source: World Pharma News - March 17, 2023 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
